Totus Medicines

Totus Medicines develops precision oral medicines, utilizing covalent small molecules for diseases with limited treatment options. Its proprietary OmniDEL discovery platform, an advanced chemical biology technology, targets historically "undruggable" mechanisms. The platform screens targets directly in their native cellular environment, optimizing efficacy and selectivity across oncology, immunology, and inflammation.

Founded in 2019 by co-founder Neil Dhawan, PhD, Totus Medicines originated from the insight that many disease targets were unreachable by traditional drug discovery. This recognition, combined with Dr. Dhawan’s expertise, drives its mission to expand small-molecule therapeutics beyond prior limitations.

Totus Medicines aims to deliver solutions for patients lacking effective treatment options. Its vision is to end untreatable diseases through advancing precision oral medicines. The company transforms patient outcomes by translating scientific breakthroughs into impactful clinical applications, offering a forward-looking approach to medical challenges.

High-Level Overview

Totus Medicines is a biotechnology company developing precision oral medicines to target "undruggable" proteins across the human genome, addressing diseases like cancers and heart conditions where 90% of potential targets have historically lacked viable drugs.[1][2] Its high-throughput platform combines covalent chemistry, ultra-high-throughput cell-based screening, and AI/ML-powered drug design to discover drugs at unprecedented volume, speed, and efficiency, with a lead product TOS-358 (a PI3Kα inhibitor) in Phase 1 trials for solid tumors such as squamous cell carcinoma of the head and neck.[1][2][3] The company serves patients with limited treatment options in oncology, immunology, and inflammation, solving the core problem of undruggable targets by building a growing, searchable catalog of precision therapies; it has raised $40M in a Series A round in December 2021 and employs 11-50 people in Emeryville, CA.[1]

Origin Story

Founded in 2019 (with some sources noting 2020), Totus Medicines emerged from the recognition that while researchers identify hundreds of disease targets daily, 90% remain undruggable, prompting the creation of its revolutionary platform to unlock them.[1][2][5] The team consists of cross-disciplinary scientists and professionals focused on bringing hope to every diagnosis, though specific founders are not detailed in available data; early efforts prioritized untreatable diseases like specific cancers and heart conditions.[1][2][4] Pivotal early traction includes securing $40M in Series A funding in December 2021 and advancing TOS-358 to Phase 1 clinical trials by 2023, alongside discovery-stage programs like AKT inhibitors for neoplasms.[1][3]

Core Differentiators

• Revolutionary Platform: Uses covalent molecules as a "universal key" for undruggable targets, integrating high-throughput cell-based screening with AI/ML to generate drugs thousands of times faster and more efficiently than traditional methods, creating a self-improving library.[1][2]
• Target Focus: Prioritizes oncology (e.g., TOS-358 for PI3Kα in solid tumors) and expands to immunology/inflammation and heart diseases, with multiple R&D efforts across cancers.[1][2][3]
• Drug Modalities: Specializes in covalent small molecules, including small molecule drugs and exploratory CRISPR/Cas9 approaches, enabling precision oral medicines.[1][3]
• Clinical Progress: Lead asset TOS-358 in Phase 1; broader pipeline in discovery for high-need areas like neoplasms.[3]

Role in the Broader Tech Landscape

Totus Medicines rides the wave of precision medicine and AI-driven drug discovery, capitalizing on advances in covalent chemistry—proven in historic drugs like penicillin and oncology therapies—to tackle the 90% of the genome deemed undruggable.[2] Timing aligns with surging biotech investment in genomic-scale platforms amid rising cancer prevalence and demand for targeted therapies, amplified by AI/ML efficiencies that accelerate R&D amid patent cliffs for blockbusters.[1][2] Market forces like regulatory support for orphan drugs and oncology innovation favor Totus, positioning it to influence the ecosystem by democratizing access to novel targets and fostering a knowledge base for future precision drugs.[1][2]

Quick Take & Future Outlook

Totus Medicines is poised to expand its pipeline beyond TOS-358, with recent press releases (e.g., January 2025) signaling momentum in oncology and immunology programs, potentially advancing more assets to clinic amid AI-enhanced discovery.[2] Trends like covalent drug resurgence and genomic mapping will shape its path, enabling broader ecosystem impact through partnerships or an eventual IPO, as hinted in pre-IPO tracking.[5] Its influence could evolve from pioneer to platform leader, transforming undruggable targets into treatable ones and redefining biotech scalability—ultimately making the entire human genome druggable as promised.[1][2]